Tharimmune, Inc. - Common StockShare · US4327052001 · THAR (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Tharimmune, Inc. - Common Stock
Analyst Grade Summary
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell
0
0
1
0
0
No Price
22.04.2026 16:59
Current Prices from Tharimmune, Inc. - Common Stock
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ
THAR
USD
22.04.2026 16:59
3,54 USD
-
Share Float & Liquidity
Free Float73,10 %
Shares Float28,9 M
Shares Outstanding39,53 M
Company Profile for Tharimmune, Inc. - Common Stock Share
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
